Filing Details

Accession Number:
0001493152-19-009014
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-06-11 17:00:26
Reporting Period:
2019-06-10
Accepted Time:
2019-06-11 17:00:26
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1582554 Matinas Biopharma Holdings Inc. MTNB () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1403497 K Adam Stern Aegis Capital Corp, Attn: Cassel Shapiro
810 Seventh Ave., 18Th Floor
New York, NY 10019
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, Par Value $0.0001 Per Share Acquisiton 2019-06-10 15,000 $0.82 3,204,483 No 4 P Indirect Held by AKS Family Partners LP
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect Held by AKS Family Partners LP
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock, Par Value $0.0001 Per Share 793,992 Direct
Common Stock, Par Value $0.0001 Per Share 300,000 Indirect Held by Pavilion Capital Partners Inc.
Common Stock, Par Value $0.0001 Per Share 300,000 Indirect Held by Piper Ventures Partners LLC
Common Stock, Par Value $0.0001 Per Share 1,750,000 Indirect Held by AKS Family Foundation, Inc.
Common Stock, Par Value $0.0001 Per Share 600,000 Indirect Held by SternAegis Ventures LLC Defined Benefit Pension Plan
Footnotes
  1. Mr. Stern disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership by Mr. Stern of the reported securities for purposes of Section 16 or any other purpose.
  2. The price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions ranged from $0.79 to $0.83, inclusive. The reporting person undertakes to provide to Matinas BioPharma Holdings, Inc., any security holder of Matinas BioPharma Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.